ResearcherHouston MethodistActive in the last 2 years
Ann Marie Leen
Matched on ORCID iD 0000-0002-4470-1760; OpenAlex author ID A5020956671; NIH RePORTER profile ID 8794068. Sources: funder_awards.
Their work
- Papers
- 4 (first author 0, last author 1)
- Trials
- 0
- Grants
- 2
- Labs led
- 1
- Collaborators
- 15
2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 grant · 2017: 1 paper, 1 grant · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper
Papers 4
- Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial. Last author DOI 10.1038/s41591-025-04043-5↗
- LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): resul… Co-author DOI 10.1016/s1470-2045(24)00079-2↗
- Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Co-author DOI 10.1016/j.ymthe.2016.10.016↗
- Engineered T cells for pancreatic cancer treatment. Co-author DOI 10.1111/j.1477-2574.2011.00344.x↗
Grants 2
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Helen E Heslop · 2 shared papers, 1 shared grant, 2017–2026 · strength 0.52
- Grant ENHANCING T CELL THERAPY OF CANCER P01CA094237↗
- Paper Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial. DOI 10.1038/s41591-025-04043-5↗
- Paper Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment … DOI 10.1016/j.ymthe.2016.10.016↗
- Cliona M. Rooney · 2 shared papers, 1 shared grant, 2017–2026 · strength 0.52
- Grant ENHANCING T CELL THERAPY OF CANCER P01CA094237↗
- Paper Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial. DOI 10.1038/s41591-025-04043-5↗
- Paper Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment … DOI 10.1016/j.ymthe.2016.10.016↗
- Brandon George Smaglo · 2 shared papers, 2024–2026 · strength 0.39
- Benjamin Musher · 2 shared papers, 2024–2026 · strength 0.39
- George Van Buren · 1 shared paper, 2026 · strength 0.22
- Angelica Loskog · 1 shared paper, 2024 · strength 0.16
- Eric Keith Rowinsky · 1 shared paper, 2024 · strength 0.16
- Emma Eriksson · 1 shared paper, 2024 · strength 0.16
- Gustav Jörgen Ullenhag · 1 shared paper, 2024 · strength 0.16
- Linda C. Sandin · 1 shared paper, 2024 · strength 0.16
- Mohamed O. Othman · 1 shared paper, 2024 · strength 0.16
- William E. Fisher · 2 shared papers, 2011–2017 · strength 0.10
- Juan F. Vera · 2 shared papers, 2011–2017 · strength 0.10
- Somala Mohammed · 1 shared paper, 2017 · strength 0.07
- Usha L. Katari · 1 shared paper, 2011 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.